China Medical System Buys Two AstraZeneca Drugs for $500 Million

China Medical System Holdings  agreed to pay $500 million for two established AstraZeneca cardiovascular drugs. The agreement includes $310 million to in-license China rights for Plendil, a hypertension drug of the calcium channel blocker class, and another $190 million for global rights (ex-US) for Imdur, an anti-angina nitrate drug. CMS markets prescription drugs in China. More details.... Stock Symbols: (HK: 0867) (NYSE: AZN) Share this with colleagues: // //